Olcegepant (also known as BIBN 4096) is a selective calcitonin gene-related peptide (CGRP) receptor antagonist investigated for the treatment of acute migraines. It works by blocking the CGRP receptor, which plays a key role in pain transmission, vasodilation, and neurogenic inflammation during migraine attacks. Clinical trials demonstrated its efficacy in reducing migraine severity when administered intravenously. However, due to poor oral bioavailability and formulation challenges, further development for commercial use was discontinued. Today, Olcegepant is primarily utilized in research settings to explore CGRP pathways and develop new migraine therapies. It offers a targeted mechanism with a potentially favorable side effect profile compared to traditional treatments.